A Phase 1 interventional study of PF-06882961 20 mg in Diabetes Mellitus, Type 2, Renal Impairment and Healthy, sponsored by Pfizer. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-05-10.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Diabetes Mellitus, Type 2 by Pfizer — 2 open to participants now, 3 under way, 3 of them phase 3. Diabetes Mellitus, Type 2 · Pfizer.
Among the 80 studies in Diabetes Mellitus, Type 2 by Pfizer, this one is the 44th largest by enrollment of the 79 interventional ones that give a count, is one of 3 that started in 2021, is one of 47 in phase 1, and was the 72nd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →2 of the 80 studies in Diabetes Mellitus, Type 2 by Pfizer are open now, in 11 countries. Recruiting first, the newest first:
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States, Brazil, Canada and 8 more countries
Ages 18+
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 50 across the 79 interventional studies, 32 across the 1 observational. Of the 77 that completed or were terminated, 39 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
1 of the studies in Diabetes Mellitus, Type 2 by Pfizer that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
Add it to your calendar (.ics) → With an account.
Among the 80 studies in Diabetes Mellitus, Type 2 by Pfizer, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will characterize the effect of varying degrees of renal impairment on the pharmacokinetics (PK), safety and tolerability of a single oral dose of PF- 06882961 compared with participants with normal renal function.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional Inclusion Criteria for Healthy Participants with Normal Renal
Function (Group 1):
Demographically comparable to participants with impaired renal function:
Attempts will be made to ensure that the male to female distribution in Group 1 is comparable to that in the pooled renal impairment groups (Cohorts 3, 4, and 5).
Additional Inclusion Criteria for T2DM Participants with Normal Renal
Function (Group 2):
Demographically comparable to participants with impaired renal function:
Additional Inclusion Criteria for T2DM Participants with Impaired Renal Function (Groups 3-5):
Exclusion Criteria:
Participants with ANY of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study specific central laboratory and confirmed by a single repeat test, if deemed necessary:
Additional Exclusion Criteria for Healthy Participants with Normal Renal
Function (Group 1):
≥6.0% at Screening visit S1; FPG ≥126 mg/dL at screening (S1); Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level ≥1.5 × upper limit of normal (ULN). Additional Exclusion Criteria for T2DM Participants with Normal Renal
Function (Group 2):
Additional Exclusion Criteria for T2DM Participants with Impaired Renal
Function (Groups 3-5) only:
Criteria for Dosing on Day 1
Participants will progress to dosing on Day 1 provided they have satisfied all the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm includes participants with normal renal function who will receive an oral dose of PF-06882961 20 milligrams (mg) on Day 1
Drug: PF-06882961 20 mg
This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with normal renal function who will receive an oral dose of PF-06882961 20 mg on Day 1
Drug: PF-06882961 20 mg
This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with mild renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
Drug: PF-06882961 20 mg
This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with moderate renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
Drug: PF-06882961 20 mg
This arm includes participants with Type 2 Diabetes Mellitus (T2DM) with severe renal impairment who will receive an oral dose of PF-06882961 20 mg on Day 1
Drug: PF-06882961 20 mg
PF-06882961 20 mg single oral dose provided in tablet form administered in a fed state on Day 1
Maximum Observed Plasma Concentration (Cmax) of Plasma PF-06882961
Cmax was the maximum observed plasma concentration and was directly observed from data.
Time frame: 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3
Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Plasma PF-06882961
AUCinf was defined as area under the plasma concentration-time curve from time zero to infinity.
Time frame: 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3
Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of Plasma PF-06882961
AUClast was area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration.
Time frame: 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3
Fraction Unbound (fu) of Plasma PF-06882961
Fu was defined as fraction of unbound drug in plasma.
Time frame: 0 (pre dose), 4 hours (post dose) on Day 1
Maximum Observed Concentration of Unbound Drug (Cmax,u) of Plasma PF-06882961
Cmax,u was defined as maximum observed concentration of unbound drug.
Time frame: 0 (pre dose), 4 hours (post dose) on Day 1
Unbound Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf,u) of Plasma PF-06882961
AUCinf,u was defined as unbound area under the plasma concentration-time profile from time zero extrapolated to infinite time.
Time frame: 0 (pre dose), 4 hours (post dose) on Day 1
Unbound Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast,u) of Plasma PF-06882961
AUClast,u was defined as unbound area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration.
Time frame: 0 (pre dose), 4 hours (post dose) on Day 1
Apparent Clearance (CL/F) of Plasma PF-06882961
Apparent Clearance After Oral Dose (CL/F) was defined as apparent clearance after oral dose on the last day of treatment period.
Time frame: 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3
Apparent Clearance of Unbound Drug After Oral Administration (CLu/F) of Plasma PF-06882961
CLu/F was defined as apparent clearance of unbound drug.
Time frame: 0 (pre dose), 4 hours (post dose) on Day 1
Apparent Volume of Distribution (Vz/F) of Plasma PF-06882961
Vz/F was defined as apparent volume of distribution.
Time frame: 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3
Unbound Vz/F (Vz,u/F) of Plasma PF-06882961
Vz,u/F was defined as apparent volume of distribution of unbound drug.
Time frame: 0 (pre dose), 4 hours (post dose) on Day 1
Time of Observed Maximum Plasma Concentration (Tmax) of Plasma PF-06882961
Tmax was defined as time to maximum observed concentration. Observed directly from data as time of first occurrence.
Time frame: 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3
Terminal Elimination Half-Life (T1/2) of Plasma PF-06882961
Plasma terminal elimination half-life (T1/2) is the time measured for the plasma concentration to decrease by one half at the terminal phase.
Time frame: 0 (pre dose), 1, 2, 3, 4, 5, 6, 8, 10, 12, 16 hours (post dose) on Day 1, 24 and 36 hours (post dose) on Day 2, 48 hours (post dose) on Day 3
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (All Causalities)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent adverse event (TEAE) means event between first dose of study treatment and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state. An SAE was an AE resulting in any of death; inpatient hospitalization; life-threatening experience; disability; congenital anomaly or deemed significant for any other reason.
Time frame: From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months)
Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality)
Laboratory test abnormalities included hematology, chemistry and urinalysis.
Time frame: From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months)
Number of Participants With Abnormal Vital Signs
The vital signs were measured included pulse rate (beats/min) and blood pressure (mmHg).
Time frame: From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months)
Number of Participants With Abnormal Electrocardiograms (ECGs)
ECG parameters included QTCF, PR interval, and QRS interval.
Time frame: From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months)
| Milestone | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| Started | 8 | 7 | 8 | 8 | 8 |
| Completed | 8 | 7 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
Cmax was the maximum observed plasma concentration and was directly observed from data.
| nanograms/milliliter (ng/mL) | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Plasma PF-06882961 | 38.80 ± 28 | 38.67 ± 58 | 39.19 ± 42 | 56.68 ± 28 | 39.18 ± 50 |
AUCinf was defined as area under the plasma concentration-time curve from time zero to infinity.
| nanograms*hour/milliliter (ng*hr/mL) | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Plasma PF-06882961 | 362.4 ± 30 | 404.8 ± 49 | 487.0 ± 19 | 543.2 ± 48 | 408.8 ± 46 |
AUClast was area under the plasma concentration time-curve from zero (pre-dose) to the last measured concentration.
| ng*hr/mL | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-Time Profile From Time Zero to Time of the Last Quantifiable Concentration (AUClast) of Plasma PF-06882961 | 359.9 ± 30 | 399.6 ± 50 | 466.3 ± 19 | 538.2 ± 44 | 404.8 ± 46 |
Fu was defined as fraction of unbound drug in plasma.
| Ratio | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| Fraction Unbound (fu) of Plasma PF-06882961 | 0.01519 ± 9 | 0.01542 ± 15 | 0.01699 ± 14 | 0.01861 ± 18 | 0.01960 ± 18 |
Cmax,u was defined as maximum observed concentration of unbound drug.
| ng/mL | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| Maximum Observed Concentration of Unbound Drug (Cmax,u) of Plasma PF-06882961 | 0.5896 ± 34 | 0.5963 ± 60 | 0.6662 ± 32 | 1.055 ± 25 | 0.7680 ± 57 |
AUCinf,u was defined as unbound area under the plasma concentration-time profile from time zero extrapolated to infinite time.
| ng*hr/mL | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| Unbound Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf,u) of Plasma PF-06882961 | 5.505 ± 37 | 6.246 ± 45 | 7.931 ± 16 | 10.01 ± 31 | 8.019 ± 50 |
AUClast,u was defined as unbound area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration.
| ng*hr/mL | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| Unbound Area Under the Plasma Concentration-Time Profile From Time Zero to the Time of the Last Quantifiable Concentration (AUClast,u) of Plasma PF-06882961 | 5.470 ± 38 | 6.162 ± 46 | 7.922 ± 14 | 10.01 ± 30 | 7.927 ± 50 |
Apparent Clearance After Oral Dose (CL/F) was defined as apparent clearance after oral dose on the last day of treatment period.
| liter per hour (L/hr) | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| Apparent Clearance (CL/F) of Plasma PF-06882961 | 55.17 ± 30 | 49.32 ± 49 | 41.08 ± 19 | 36.83 ± 48 | 48.93 ± 46 |
CLu/F was defined as apparent clearance of unbound drug.
| L/hr | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| Apparent Clearance of Unbound Drug After Oral Administration (CLu/F) of Plasma PF-06882961 | 3631 ± 37 | 3200 ± 45 | 2525 ± 16 | 2000 ± 31 | 2494 ± 50 |
Vz/F was defined as apparent volume of distribution.
| liter (L) | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) of Plasma PF-06882961 | 600.8 ± 59 | 552.3 ± 89 | 372.5 ± 38 | 438.4 ± 85 | 565.9 ± 48 |
Vz,u/F was defined as apparent volume of distribution of unbound drug.
| Liter | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| Unbound Vz/F (Vz,u/F) of Plasma PF-06882961 | 39530 ± 68 | 35810 ± 84 | 22890 ± 30 | 23800 ± 63 | 28900 ± 51 |
Tmax was defined as time to maximum observed concentration. Observed directly from data as time of first occurrence.
| hour (hr) | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| Time of Observed Maximum Plasma Concentration (Tmax) of Plasma PF-06882961 | 5.00 (3.00 to 8.00) | 5.00 (5.00 to 8.13) | 6.00 (3.00 to 12.0) | 5.50 (4.00 to 6.00) | 5.00 (4.00 to 6.00) |
Plasma terminal elimination half-life (T1/2) is the time measured for the plasma concentration to decrease by one half at the terminal phase.
| hr | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| Terminal Elimination Half-Life (T1/2) of Plasma PF-06882961 | 8.111 ± 3.4828 | 8.139 ± 2.5640 | 6.640 ± 2.6551 | 8.907 ± 4.0497 | 8.058 ± 0.84962 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent adverse event (TEAE) means event between first dose of study treatment and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state. An SAE was an AE resulting in any of death; inpatient hospitalization; life-threatening experience; disability; congenital anomaly or deemed significant for any other reason.
| Participants | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| Participants with adverse events | 1 | 6 | 1 | 2 | 2 |
| Participants with serious adverse events | 0 | 0 | 0 | 0 | 0 |
| Participants with severe adverse events | 0 | 0 | 0 | 0 | 0 |
| Participants discontinued from study due to adverse events | 0 | 0 | 0 | 0 | 0 |
| Participants discontinued study drug due to AE and continue Study | 0 | 0 | 0 | 0 | 0 |
| Participants with dose reduced or temporary discontinuation due to adverse events | 0 | 0 | 0 | 0 | 0 |
Laboratory test abnormalities included hematology, chemistry and urinalysis.
| Participants | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| Hematology: Erythrocytes (10^6/mm^3) < 0.8x LLN | 0 | 0 | 0 | 0 | 1 |
| Hematology: Ery. Mean Corpuscular HGB Concentration (g/dL) < 0.9x LLN | 0 | 0 | 2 | 0 | 0 |
| Hematology: Lymphocytes (10^3/mm^3) < 0.8x LLN | 0 | 0 | 0 | 0 | 1 |
| Hematology: Eosinophils (10^3/mm^3) > 1.2x ULN | 0 | 0 | 1 | 1 | 0 |
| Clinical Chemistry: Bilirubin (mg/dL) > 1.5x ULN | 1 | 0 | 0 | 0 | 0 |
| Clinical Chemistry: Blood Urea Nitrogen (mg/dL) > 1.3x ULN | 0 | 0 | 4 | 5 | 8 |
| Clinical Chemistry: Creatinine (mg/dL) > 1.3x ULN | 0 | 0 | 0 | 3 | 8 |
| Clinical Chemistry: Urate (mg/dL) > 1.2x ULN | 0 | 0 | 1 | 1 | 0 |
| Clinical Chemistry: Magnesium (mg/dL) < 0.9x LLN | 0 | 0 | 0 | 1 | 0 |
| Clinical Chemistry: Phosphate (mg/dL) > 1.2x ULN | 0 | 0 | 0 | 0 | 2 |
| Clinical Chemistry: Bicarbonate (mEq/L) < 0.9x LLN | 0 | 0 | 0 | 0 | 1 |
| Clinical Chemistry: Glucose (mg/dL) > 1.5x ULN | 0 | 4 | 3 | 5 | 3 |
| Clinical Chemistry: Triacylglycerol Lipase (U/L) > 1.5x ULN | 0 | 2 | 0 | 1 | 2 |
| Urinalysis: URINE Glucose (Scalar) ≥ 1 | 0 | 1 | 2 | 2 | 2 |
| Urinalysis: URINE Protein (Scalar) ≥ 1 | 0 | 0 | 0 | 4 | 4 |
| Urinalysis: Leukocyte Esterase ≥ 1 | 0 | 1 | 0 | 0 | 1 |
| Urinalysis: Hyaline Casts (/LPF) > 1 | 0 | 0 | 0 | 0 | 1 |
| Urinalysis: Bacteria (/HPF) > 20 | 1 | 0 | 0 | 0 | 0 |
The vital signs were measured included pulse rate (beats/min) and blood pressure (mmHg).
| Participants | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| SITTING SYSTOLIC BLOOD PRESSURE (MMHG): Value < 90mmHg | 0 | 0 | 0 | 0 | 0 |
| SITTING SYSTOLIC BLOOD PRESSURE (MMHG): Chg ≥ 30mmHg increase | 0 | 0 | 0 | 1 | 1 |
| SITTING SYSTOLIC BLOOD PRESSURE (MMHG): Chg ≥ 30mmHg decrease | 0 | 0 | 0 | 0 | 1 |
| SITTING DIASTOLIC BLOOD PRESSURE (MMHG): Value < 50 mmHg | 0 | 0 | 0 | 0 | 0 |
| SITTING DIASTOLIC BLOOD PRESSURE (MMHG): Chg ≥ 20mmHg increase | 0 | 0 | 1 | 1 | 1 |
| SITTING DIASTOLIC BLOOD PRESSURE (MMHG): Chg ≥ 20mmHg decrease | 0 | 0 | 0 | 0 | 0 |
| PULSE RATE (BPM): Value < 40 bpm | 0 | 0 | 0 | 0 | 0 |
| PULSE RATE (BPM): Value > 120 bpm | 0 | 0 | 0 | 0 | 0 |
ECG parameters included QTCF, PR interval, and QRS interval.
| Participants | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment |
|---|---|---|---|---|---|
| PR INTERVAL NOT OTHERWISE SPECIFIED (MSEC): Value ≥ 300 | 0 | 0 | 0 | 0 | 0 |
| PR INTERVAL NOT OTHERWISE SPECIFIED (MSEC): %Chg ≥ 25/50% | 0 | 0 | 0 | 0 | 0 |
| QRS INTERVAL NOT OTHERWISE SPECIFIED (MSEC): Value ≥ 140 | 0 | 1 | 0 | 0 | 0 |
| QRS INTERVAL NOT OTHERWISE SPECIFIED (MSEC): %Chg ≥ 50% | 0 | 0 | 0 | 0 | 0 |
| QTCF NOT OTHERWISE SPECIFIED (MSEC): 450 < Value ≤ 480 | 0 | 0 | 0 | 1 | 2 |
| QTCF NOT OTHERWISE SPECIFIED (MSEC): 480 < Value ≤ 500 | 0 | 1 | 0 | 0 | 0 |
| QTCF NOT OTHERWISE SPECIFIED (MSEC): Value > 500 | 0 | 0 | 0 | 0 | 0 |
| QTCF NOT OTHERWISE SPECIFIED (MSEC): 30 < Chg ≤ 60 | 0 | 0 | 0 | 0 | 0 |
| QTCF NOT OTHERWISE SPECIFIED (MSEC): Chg > 60 | 0 | 0 | 0 | 0 | 0 |
Collected over From the first dose of study intervention to the last dose of study treatment date +35 days (up to 13 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Healthy and Normal Renal Function | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| T2DM Normal Renal Function | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| T2DM Mild Renal Impairment | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| T2DM Moderate Renal Impairment | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| T2DM Severe Renal Impairment | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Total | 0/39 (0%) | 0/39 (0%) | 12/39 (30.8%) |
| Event | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment | Total |
|---|---|---|---|---|---|---|
| PolyuriaRenal and urinary disorders | 0/8 | 2/7 | 0/8 | 0/8 | 0/8 | 2/39 |
| DiarrhoeaGastrointestinal disorders | 0/8 | 0/7 | 0/8 | 2/8 | 0/8 | 2/39 |
| NauseaGastrointestinal disorders | 1/8 | 1/7 | 0/8 | 1/8 | 1/8 | 4/39 |
| FatigueGeneral disorders | 0/8 | 1/7 | 0/8 | 0/8 | 0/8 | 1/39 |
| Upper respiratory tract infectionInfections and infestations | 0/8 | 1/7 | 0/8 | 0/8 | 0/8 | 1/39 |
| Lipase increasedInvestigations | 0/8 | 1/7 | 0/8 | 0/8 | 0/8 | 1/39 |
| SARS-CoV-2 test positiveInvestigations | 0/8 | 1/7 | 0/8 | 0/8 | 0/8 | 1/39 |
| Increased appetiteMetabolism and nutrition disorders | 0/8 | 1/7 | 0/8 | 0/8 | 0/8 | 1/39 |
| PolydipsiaMetabolism and nutrition disorders | 0/8 | 1/7 | 0/8 | 0/8 | 0/8 | 1/39 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 0/8 | 1/7 | 0/8 | 0/8 | 0/8 | 1/39 |
All enrolled participants who received at least one dose of study intervention.
| Age, Continuous(Years) | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment | Total |
|---|---|---|---|---|---|---|
| Mean | 57.1 ± 2.30 | 64.1 ± 7.17 | 68.0 ± 10.90 | 67.0 ± 9.09 | 59.8 ± 4.98 | 63.2 ± 8.31 |
| Sex: Female, Male(Participants) | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 4 | 5 | 4 | 2 | 18 |
| Male | 5 | 3 | 3 | 4 | 6 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 0 | 2 | 3 | 4 | 14 |
| Not Hispanic or Latino | 3 | 7 | 6 | 5 | 4 | 25 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Healthy and Normal Renal Function | T2DM Normal Renal Function | T2DM Mild Renal Impairment | T2DM Moderate Renal Impairment | T2DM Severe Renal Impairment | Total |
|---|---|---|---|---|---|---|
| White | 6 | 4 | 7 | 7 | 4 | 28 |
| Black or African American | 1 | 3 | 1 | 1 | 4 | 10 |
| American Indian or Alaska Native | 1 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Jan 2021 to primary completion in Feb 2022, 13 months.
Results were first posted in May 2024, 2 years 2 months after primary completion.
Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 13 months is above that.
Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Danuglipron